{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02579876: Phase 2 Interventional Completed Eosinophilic Esophagitis
(2015)
Source URL:
Class:
MIXTURE
Class:
MIXTURE
Orientiparcin is a mixture of two glycopeptide antibiotic complexes: orienticins A and D. Orientiparcin showed a broad spectrum of antibacterial activity. However, information about the current use of this drug is not available.
Status:
Investigational
Source:
NCT04487860: Phase 2 Interventional Completed Non-segmental Vitiligo
(2021)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
PLoS Negl Trop Dis. Oct 2016;10(10):e0005056.: Not Applicable Human clinical trial Completed Tungiasis/epidemiology/parasitology
Source URL:
Class:
MIXTURE
Clorfenvinfos (chlorfenvinphos) is an organophosphate insecticide, which is used to control insect pests on livestock, and to control household pests such as flies, fleas, and mites. Clorfenvinfos was sold under trade names including Birlane®, Dermaton®, Sapercon®, Steladone®, and Supona®. In 1991 all products containing clorfenvinfos were banned in the USA. Toxicity of clorfenvinfos is due to inhibition of acetylcholinesterase. Inhibition of cholinesterase activity results in the accumulation of acetylcholine at muscarinic and nicotinic receptors. This leads to continuous or excessive stimulation of cholinergic fibers in the post-ganglionic parasympathetic nerve endings, neuromuscular junctions of the skeletal muscles, resulting in hyperpolarization of nerve or muscle fibers and receptor desensitization until hydrolysis of the phosphorylated cholinesterase occurs. In some cases, a dealkylation and stabilization of the phosphorylated enzyme (“aging”) occur such that hydrolysis can no longer take place and the enzyme is irreversibly inhibited. In such cases, the return of acetylcholinesterase activity parallels the time required to resynthesize this enzyme.
Status:
Investigational
Source:
NCT04325035: Phase 2 Interventional Completed Cardiogenic Shock
(2020)
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Istaroxime is a novel intravenous agent with luso-inotropic properties that acts by inhibition of Na( )/K( ) adenosine triphosphatase and stimulation of sarco/ endoplasmic reticulum calcium ATPase isoform 2. It is significantly decreased left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, heart rate and increased systolic blood pressure and cardiac index with no change in neurohormones, renal function or troponin I. Istaroxime has successfully concluded phase II clinical trials in cardiac failure patients. Istaroxime induced apoptosis, affected the key proliferative and apoptotic mediators c-Myc and caspase-3 and modified actin cytoskeleton dynamics and RhoA activity in prostate cancer cells – this provides novel insights into the anti-cancer properties of istaroxime further supporting the development of this agent as a novel anti-cancer drug candidate.
Status:
Investigational
Source:
NCT01528241: Phase 1 Interventional Completed Depression
(2008)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03406364: Phase 1 Interventional Completed Solid Tumor
(2018)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT00718692: Phase 2 Interventional Completed Immune Thrombocytopenic Purpura
(2008)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT04361617: Not Applicable Interventional Completed Metabolic Syndrome
(2021)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT04373031: Phase 2 Interventional Active, not recruiting Breast Cancer
(2020)
Source URL:
Class:
MIXTURE